I-Ruxolitinib iwuhlobo lokwelapha oluqondiswe ngomlomo olubizwa ngokuthi i-kinase inhibitor futhi isetshenziselwa kakhulu ukwelapha izifo ezifana ne-graft-versus-host disease, i-erythroblastosis, kanye ne-myelofibrosis enobungozi obuphakathi nendawo, kuyilapho ukhilimu i-Ruxolitinib iyi-agent ye-dermatological esetshenziswayo. ngqo esikhumbeni ukwelapha i-eczema, i-vitiligo, i-atopic dermatitis, nempandla. Nakuba i-Ruxolitinib ne-Ruxolitinib cream ihluke kakhulu komunye nomunye, idideka kalula ngoba inegama elifanayo. I-Changzhou Pharmaceutical Factory (CPF), ehamba phambiliUmphakeli we-RuxolitinibeShayina, lapha kuhlaziya umehluko phakathi kwazo ngokwezici ezintathu ezinkulu ukukusiza ukuthi wazi okwengeziwe ngazo.
1. Inkomba
I-Ruxolitinibyavunywa yi-FDA ngoNovemba 2011 kanye neKhomishini YaseYurophu ngo-Agasti 2012 futhi iwuhlobo lomuthi ohlosiwe onezinkomba eziqondile. Isetshenziselwa ukwelapha iziguli ezihlushwa izinhlobo ezintathu zezifo, okuhlanganisa isifo se-steroid-refractory acute graft-versus-host, i-erythroblastosis, kanye ne-moderate-to-high risk myelofibrosis (MF). Kodwa ukhilimu we-Ruxolitinib usesigabeni sokuthuthukiswa futhi uhluleka ukuya emakethe, ngakho-ke iyisidakamizwa se-topical sokwelapha isifo se-shin kanye nempandla futhi asinazo izinkomba ezivunyelwe okwamanje. Kodwa-ke, ucwaningo luye lwabonisa ukusebenza kahle komtholampilo kwe-Ruxolitinib cream ekwelapheni i-vitiligo, i-atopic dermatitis kanye nempandla enzima.
2. Indlela yokufaka isicelo
I-Ruxolitinib iyi-oral kinase inhibitor esebenza njenge-molecule encane inhibitor ye-protein kinases JAK1 ne-JAK2, futhi iyisidakamizwa sokuqala esigunyazwe yi-FDA ukwelapha i-myelofibrosis. Kodwa ukhilimu we-Ruxolitinib uwukhilimu osetshenziswayo ohluke kakhulu ku-Ruxolitinib ngendlela osetshenziswa ngayo.
3. Umphumela ohlangothini
I-Ruxolitinib inemiphumela emibi ecacile. Imiphumela evame kakhulu ye-hematological ehlotshaniswa nokusetshenziswa kwayo ukunciphisa i-platelet count kanye ne-anemia, futhi imiphumela engeyona eye-hematological evame kakhulu i-petechiae, isiyezi, nekhanda elibuhlungu. Kodwa-ke, ukhilimu we-Ruxolitinib usesesivivinyweni somtholampilo, ngakho-ke imiphumela yayo emibi ayinqunywa.
Xhumana ne-CPF ukuze uthole i-Ruxolitinib ngentengo efinyelelekayo, futhi uhambele umkhankaso wokuqashwa kokuhlolwa komtholampilo ukuze uthole ukhilimu we-Ruxolitinib mahhala.
Isikhathi sokuthumela: May-12-2022